Coronavirus India Update: Now Covishield and Covaxin will also be available in the market, DCGI has given conditional approval

Publish Date: 27 Jan, 2022 |

The Covid Vaccine is playing a decisive role in the war against the Coronavirus pandemic. The Drug Controller General of India (DCGI) of India has approved the conditional market launch of Covishield and Covaxin. This does not mean that corona vaccines will soon be available in stores, however, they will be able to buy the vaccine from hospitals and clinics and get it installed there. 

According to sources the covishield and Covaxin Vaccinations will cost around Rs 275 per dose. They have asked the cost to be easily affordable for the public. Till now, the cost of Covexin in private hospitals is Rs 1200 per dose, whereas the covishield is Rs 780 per dose. They are inclusive of service tax of Rs 150. Central Health Minister Dr. Mansukh Mandaviya has said that “The @CDSCO_INDIA_INF has now upgraded the permission for COVAXIN and Covishield from restricted use in emergency situations to normal new drug permission in the adult population with certain conditions.” He also said that “The conditions include supply for programmatic settings including registration on the CoWin platform and to continue to submit safety data on a six-monthly basis.”

Before this Pfizer in the US and Estrogenica in Britain had received market approval. Last year in October the Serum Institute of India requested to approve the market launch for Covishield. Bharat Biotech also asked for approval for Covaxin. 


Related videos

यह भी पढ़ें

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy.Accept